Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9357
Title: Evidence for cardioprotective, renoprotective, and vasculoprotective effects of vasopeptidase inhibitors in disease.
Austin Authors: Kubota, E;Dean, Rachael G;Hubner, R A;Balding, Leanne C;Johnston, Colin I;Burrell, Louise M 
Affiliation: Department of Medicine, University of Melbourne, Austin and Repatriation Medical Centre, Studley Road, Heidelberg 3084, Victoria, Australia
Issue Date: 1-Dec-2001
Publication information: Current Hypertension Reports; 3 Suppl 2(): S31-3
Abstract: In both the natriuretic peptide and renin-angiotensin systems, peptidases play an important role in the inactivation or activation of the system. Angiotensin-converting enzyme is responsible for the conversion of angiotensin I to angiotensin II, while neutral endopeptidase is one of the pathways involved in the degradation of the natriuretic peptides. The vasopeptidase inhibitors, which simultaneously inhibit neutral endopeptidase and angiotensin-converting enzyme, appear to offer distinct therapeutic advantages in treating hypertension, heart failure, and endothelial dysfunction.
Gov't Doc #: 11716804
URI: http://ahro.austin.org.au/austinjspui/handle/1/9357
URL: https://pubmed.ncbi.nlm.nih.gov/11716804
Type: Journal Article
Subjects: Angiotensin-Converting Enzyme Inhibitors.pharmacology
Cardiotonic Agents.pharmacology
Endothelium, Vascular.drug effects
Heart.drug effects
Heart Failure.drug therapy
Humans
Hypertension.drug therapy
Kidney.drug effects
Kidney Failure, Chronic.drug therapy.etiology
Neprilysin.antagonists & inhibitors
Renin-Angiotensin System.drug effects
Appears in Collections:Journal articles

Show full item record

Page view(s)

14
checked on Dec 5, 2022

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.